Last reviewed · How we verify
ISIS-FXIRx Dose #3 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
ISIS-FXIRx Dose #3 (ISIS-FXIRx Dose #3) — Ionis Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ISIS-FXIRx Dose #3 TARGET | ISIS-FXIRx Dose #3 | Ionis Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ISIS-FXIRx Dose #3 CI watch — RSS
- ISIS-FXIRx Dose #3 CI watch — Atom
- ISIS-FXIRx Dose #3 CI watch — JSON
- ISIS-FXIRx Dose #3 alone — RSS
Cite this brief
Drug Landscape (2026). ISIS-FXIRx Dose #3 — Competitive Intelligence Brief. https://druglandscape.com/ci/isis-fxirx-dose-3. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab